Gene-set analysis based on the pharmacological profiles of drugs to identify repurposing opportunities in schizophrenia
| Autor: | David A. Collier, Gerome Breen, Lewis R. Vidler, Younes Mokrab, Simone de Jong |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Drug Metoclopramide media_common.quotation_subject Genome-wide association study Biology Bioinformatics 03 medical and health sciences medicine Humans Genetic Predisposition to Disease Pharmacology (medical) Repurposing media_common Genetic association Pharmacology Drug Repositioning medicine.disease Trifluoperazine Psychiatry and Mental health Drug repositioning 030104 developmental biology Drug development Schizophrenia Drug Design Neratinib Quinolines Antipsychotic Agents Genome-Wide Association Study medicine.drug |
| Zdroj: | Journal of Psychopharmacology. 30:826-830 |
| ISSN: | 1461-7285 0269-8811 |
| Popis: | Genome-wide association studies (GWAS) have identified thousands of novel genetic associations for complex genetic disorders, leading to the identification of potential pharmacological targets for novel drug development. In schizophrenia, 108 conservatively defined loci that meet genome-wide significance have been identified and hundreds of additional sub-threshold associations harbour information on the genetic aetiology of the disorder. In the present study, we used gene-set analysis based on the known binding targets of chemical compounds to identify the ‘drug pathways’ most strongly associated with schizophrenia-associated genes, with the aim of identifying potential drug repositioning opportunities and clues for novel treatment paradigms, especially in multi-target drug development. We compiled 9389 gene sets (2496 with unique gene content) and interrogated gene-based p-values from the PGC2-SCZ analysis. Although no single drug exceeded experiment wide significance (corrected p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|